Author, Subjects, Keywords

Cited Author

 
 
   » By Author or Editor
 » Browse Author by Alphabet
 » By Journal
 » By Subjects
 » Malaysian Journals
 » By Type
 » By Year
 » By Latest Additions
 
 
   » By Author
 » Top 20 Authors
 » Top 20 Article
 » Top Journal Cited
 » Top Article Cited
 » Journal Citation Statistics
 » Usage Since Sept 2007


 
 
 

Login | Create Account

Prevalence and risk factors for menstrual disorders among systemic lupus erythematosus patients

Fatnoon N.N.A., and Azarisman S.M.S., and Zainal D., (2008) Prevalence and risk factors for menstrual disorders among systemic lupus erythematosus patients. Singapore Medical Journal, 49 (5). pp. 413-418. ISSN 0037-5675

[img]
Preview
PDF (Original Article) - Requires a PDF viewer such as GSview, Xpdf or Adobe Acrobat Reader
194Kb

Official URL: http://smj.sma.org.sg

Affiliations

International Islamic University Malaysia. Kulliyah of Medicine
International Islamic University Malaysia. Kulliyah of Medicine
Hospital Universiti Sains Malaysia. Dept. of Medicine

Abstract

Introduction: This study aims to determine the prevalence and the types of menstrual disorders among patients with systemic lupus erythematosus(SLE) and to identify factors that influence their development. Methods: 61 patients with SLE were enrolled into a cross-sectional, observational study at the medical outpatient clinic, Hospital Universiti Sains Malaysia. A total of 120 healthy women were selected randomly to act as the control group. A questionnaire was administered, vital signs were recorded, and blood was evaluated for routine investigations. A review of past medical records was also undertaken. Results: The mean age and standard deviation for the study group was 33.23 +/- 10.96 years, the majority being ethnic Malays. 75 percent had a severe SLE disease activity index score on initial presentation, and 59 percent were on cyclophosphamide. 49 percent of the study population had menstrual irregularities, of which 60 percent had sustained amenorrhoea. Nine patients with sustained amenorrhoea had hormonal assays, which confirmed the diagnosis of premature menopause. Conclusion: This study showed that SLE patients had a higher risk of developing menstrual irregularities compared to the normal/healthy population. The risk was higher in the older age group (greater than 30 years old) and those on cyclophosphamide therapy, especially those with a cumulative dose of more than 10 g. Sustained amenorrhoea was the commonest irregularity and a majority of them had confirmed premature menopause.

Item Type:Journal
Keywords:amenorrhoea, menstrual disorders, premature menopause, systemic lupus erythematosus
Subjects:R Medicine, Dentistry, Pharmacy, Nursing
ID Code:11148

1. Mills JA. Systemic Lupus Erythematosus. N Eng J Med 1994; 330:1871-9.

2. Lamont DW, Lai MK, Silber SH. Systemic Lupus Erythematosus. In: eMedicine [online]. Available at: www.emedicine.com/emerg/topic564.htm. Accessed January 31, 2007.

3. Buyon JP, Petri MA, Kim MY, et al; SELENA Investigators. Estrogen/cyclic progesterone replacement is associated with an increased rate of mild/moderate but not severe flares in SLE. Ann Intern Med 2005; 142:953-62.

4. Treloar AE, Boynton RE, Behn BG, Brown BW. Variation of the human menstrual cycle through reproductive life. Int J Fertil 1967;12(1 pt 2):77-126.

5. Nelson LM, Bakalov V, Pastor C. Amenorrhea. In: eMedicine [online]. Available at: www.emedicine.com/medtopic117.htm. Accessed January 31, 2007.

6. Medeiros MM, Silveira VA, Menezes AP, Carvalho RC. Risk factors for ovarian failure in patients with systemic lupus erythematosus. Braz J Med Biol Res 2001; 34:1561-8.

7. Moncayo-Naveda H, Moncayo R, Benz R, Wolf A, Lauritzen CH. Organ specific antibodies against ovary in patients with systemic lupus erythematosus. Am J Obstet Gynecol 1989; 160(5pt 1):1227-9.

8. Pasoto SG, Viana VS, Mendonca BB, Yoshinari NH, Bonfa E. Anticorpus luteum antibody: a novel serological marker for ovarian dysfunction in systemic lupus erythematosus? J Rheumatol 1999;26:1087-93.

9. Boumpas DT, Austin HA 3rd, Vaughan EM, at al. Risk for sustained amenorrhea in patients with systemic lupus erythematosus receiving intermittent pulse cyclophosphamide therapy. Ann Intern Med 1993; 119:366-9.

10. Gonzalez-Crespo MR, Gomez-Reino JJ, Merino R, et al. Menstrual disorders in girls with systemic lupus erythematosus treated with cyclophosphamide. Br J Rheumatol 1995; 34:737-41.

11. Somers EC, Marder W, Christman GM, Ognenovski V, McCune WJ. Use of a gonadotropin-releasing hormone analog for protection against premature ovarian failure during cyclophosphamide therapy in women with severe lupus. Arthritis Rheum 2005; 52:2761-7.

12. Bombardier C, Gladman DD, Urowitz MB, Caron D, Chang CH. Derivation of the SLEDAI. A disease activity index for lupus patients. The Committee on Prognosis Studies in SLE. Arthritis Rheum 1992; 35:630-40.

13. Swaak AJG, Nossent JC, Bronsveld W, et al. Systemic lupus erythematosus outcome and survival; Dutch experience with 10 patients studied prospectively. Ann Rheum Dis 1989; 48:447-54.

14. Ioannidis JPA, Katsifis GE, Tzioufas AG, Moutsopoulos HM. Predictors of sustained amenorrhea from pulsed intravenous cyclophosphamide in premenopausal women with systemic lupus erythematosus. J.Rheumatol 2002; 29:2129-35.

15. Ioannidis JP, Boki KA, Katsorida ME, et al. Remission, relapse, and re-remission of proliferative lupus nephritis treated with cyclophosphamide. Kidney Int 2000; 57:258-64.

16. Park MC, Park YB, Jung SY, Chung IH, Choi KH, Lee SK. Risk of ovarian failure and pregnancy outcome in patients with lupus nephritis treated with intravenous cyclophosphamide pulse therapy. Lupus 2004; 13:569-74.

17. Dhabhai R, Kalla G, Singhi MK, Ghiya BC, Kachhawa D. Dexamethasone-cyclophosphamide pulse therapy in systemic lupus erythematosus. Indian J Dermatol Venereol Leprol 2005;71:9-13.

18. Lower EE, Blau R, Gazder P, Tummala R. The risk of premature menopause induced by chemotherapy for early breast cancer. J Womens Health Gend Based Med 1999; 8:949-54.

19. Wang CL, Wang F, Bosco JJ. Ovarian failure in oral cyclophosphamide treatment for systemic lupus erythematosus. Lupus 1995; 4:11-14.

20. Lim GS, Petri M, Goldman D. Menstruation and systemic lupus erythematosus: a case-control study. Arthritis Rheum 1993; 36 (5suppl):R23.

21. Liu G, Chen Y, Wang L, et al. [The risk of sustained amenorrhea in patients with systemic lupus erythematosus receiving intermittent pulse cyclophosphamide therapy.] Hua Xi Yi Ke Da Xue Xue Bao 2001; 32:294-5. Chinese.

22. Katsifis GE, Tzioufas AG. Ovarian failure in systemic lupus erythematosus patients treated with pulsed intravenous

cyclophosphamide. Lupus 2004; 13:673-8.

Repository Staff Only: item control page
 
 
 
 
 
 
© Copyright 2007 MyAIS Faculty of Computer Science and Information Technology, University of Malaya – All Rights Reserved. Malaysian Abstracting and Indexing System is powered by EPrints 3 which is developed by the School of Electronics and Computer Science at the University of Southampton. More information and software credits.